ПРЕПАРАТЫ РАСТОРОПШИ: НОВЫЕ ОБЛАСТИ ПРИМЕНЕНИЯ
https://doi.org/10.51523/2708-6011.2010-7-1-29
Аннотация
В настоящее время наблюдается рост числа экспериментальных и клинических исследований, связанный с открытием новых свойств препаратов расторопши, применяемых в медицине в качестве гепатопротекторов. Активно изучаются механизмы противоопухолевого действия основного действующего компонента данного лекарственного растения - силимарина. Предлагаемый обзор освещает возможности применения препаратов расторопши при различных патологических состояниях.
Ключевые слова
Об авторах
Ю. И. Брель
Гомельский государственный медицинский университет
Беларусь
Беларусь
А. Н. Лызиков
Гомельский государственный медицинский университет
Беларусь
Беларусь
Э. С. Питкевич
Гомельский государственный медицинский университет
Беларусь
Беларусь
Список литературы
1. Pharmacology of Silymarin / F. Fraschini [et al.] // Clin. Drug Invest. - 2002. - Vol. 22, № 1. - P. 51-65.
2. Ramasamy, K. Multitargeted therapy of cancer by silymarin / K. Ramasamy K. R. Agarwal // Cancer Lett. - 2008. - Vol. 269, № 2. - Р. 352-362.
3. Zi, X. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention / X. Zi, R. Agarwal // Proc Natl Acad Sci USA. - 1999. - Vol. 96, № 13. - P. 7490-7495.
4. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages / A. Tyagi [et al.] // Carcinogenesis. - 2004. - Vol. 25, № 9. - P. 1711-1720.
5. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells / Agarwal C [et al.] // Oncogene. - 2003. - Vol. 22, № 51. - P. 8271-8282.
6. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins / X. Zi [et al.] // Clin. Cancer Res. - 1998. - Vol. 4, № 4. - Р. 1055-1064.
7. Silibinin efficacy against human hepatocellular carcinoma / L. Varghese [et al.] // Clin Cancer Res. - 2005. - Vol. 11, № 23. - P. 8441-8448.
8. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin / R. P. Singh [et al.] // Clin. Cancer Res. - 2008. - Vol. 14, № 1. - P. 300-308.
9. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line / S. H. Yang [et al.] // J. Surg. Res. - 2003. - Vol. 113, № 1. - Р. 133-138.
10. Effect of silibinin on the growth and progression of primary lung tumors in mice / R. P. Singh [et al.] // J. Natl. Cancer Inst. - 2006. - Vol. 98, № 12. - P. 846-855.
11. Antitumour activity of the silybinphosphatidylcholine complex, IdB 1016, against human ovarian cancer / D. Gallo [et al.] // Eur J. Cancer. - 2003. - Vol. 39, № 16. - P. 2403-2410.
12. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2 / S. C. Chu [et al.] // Mol. Carcinog. - 2004. - Vol. 40, № 3. - P. 143-149.
13. Kren, V. Silybin And Silymarin - new effects and applications / V. Kren, D. Walterova // Biomed. Papers. - 2005. - Vol. 149, № 1. - P. 29-41.
14. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP // W. Zhu [et al.] // Carcinogenesis. - 2001. - Vol. 22, № 9. - P. 1399-1403.
15. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin / G. Scambia [et al.] // Eur. J. Cancer. - 1996. - Vol. 32, № 5. - P. 877-882.
16. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance / R. P. Singh [et al.] // Clin. Cancer Res. - 2004. - Vol. 10, № 24. - P. 8641-8647.
17. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells / X. Zi [et al.] // Cancer Res. - 2000. - Vol. 60, № 20. - P. 5617-5620.
18. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels / R. P. Singh [et al.] // Cancer Res. - 2002. - Vol. 62, № 11. - P. 3063-3069.
19. Dietary supplementation with silymarin inhibits 3,2′-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats / H. Kohno [et al.] // Clin. Cancer Res. - 2005. - Vol. 11, № 13. - P. 4962-4967.
20. Protective effects of silymarin against photocarcinogenesis in a mouse skin model / S. K. Katiyar [et al.] // J Natl Cancer Inst. - 1997. - Vol. 89, № 8. - P. 556-566.
21. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice / M. Gu [et al.] // Cancer Res - 2007. - Vol.67, № 7. - P. 3483-3491.
22. Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice / P. Q. Vinh [et al.] // Jpn J Cancer Res. - 2002. - Vol. 93, № 1. - P. 42-49.
23. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats / H. Kohno [et al.] // Int. J. Cancer. - 2002. - Vol. 101, № 5. - P. 461-468.
24. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats / G. Ramakrishnan [et al.] // Chem Biol Interact. - 2006. - Vol. 161, № 2. - P. 104-114.
25. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements / B. Malewicz [et al.] // Carcinogenesis. - 2006. - Vol. 27, № 9. - P. 1739-1747.
26. Protective effect of silymarin on oxidative stress in rat brain / C. Nencini [et al.] // Phytomedicine. - 2007. - Vol. 14, № 2-3. - P. 129-135.
27. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture // S. Kittur [et al.] // J Mol Neurosci. - 2002. - Vol. 18, № 3. - P. 265-269.
28. Silymarin protects dopaminergic neurons against lip polysaccharide-induced neurotoxicity by inhibiting microglia activation / M. J. Wang [et al.] // Eur J Neurosci. - 2002. - Vol. 16, № 11. - P. 2103-2112.
29. Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis / K. Min [et al.] // Arch Pharm Res. - 2007. - Vol. 30, № 10. - P. 1265-1272.
30. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I Silymarin and its flavonolignans / S. Chlopcikova [et al.] // Phytother Res. - 2004. - Vol. 18, № 2. - P. 107-110.
31. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats / V. Krecman [et al.] // Planta Med. - 1998. - Vol. 64, № 2. - P. 138-142.
32. Silymarin inhibits TNF-α-induced expression of adhesion molecules in human umbilical vein endothelial cells / J. S. Kang [et al.] // FEBS Lett. - 2003. - Vol. 550, № 1-3. - P. 89-93.
33. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells / J. Sonnenbichler [et al.] // J Pharm Exp Ther. - 1999. - Vol. 290, № 3. - P. 1375-1383.
34. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide antitumour activity / C. Bokemeyer [et al.] // Br J Cancer. - 1996. - Vol. 74, № 12. - P. 2036-2041.
35. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin/ C. Soto [et al.] // Comp Biochem Physiol. - 1998. - Vol. 119, № 2. - P 125-129.
36. Silymarin induces recovery of pancreatic function after alloxan damage in rats / C. Soto [et al.] // Life Sci. - 2004. - Vol. 75, № 18. - P. 2167-2180.
37. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase / B. Guigas [et al.] // Cell Physio. Biochem. - 2007. - Vol. 20, № 6. - P. 925-934.
38. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients / M. Velussi [et al.] // J Hepatol. - 1997. - Vol. 26, № 4. - P. 871-879.
Рецензия
Для цитирования:
Брель Ю.И., Лызиков А.Н., Питкевич Э.С. ПРЕПАРАТЫ РАСТОРОПШИ: НОВЫЕ ОБЛАСТИ ПРИМЕНЕНИЯ. Проблемы здоровья и экологии. 2010;(1):129-134. https://doi.org/10.51523/2708-6011.2010-7-1-29
For citation:
Brel Y.I., Lyzikov A.N., Pitkevich E.S. HETRBAL PREPARATIONS FROM MILK THISTLE: NEW FIELDS OF APPLICATION. Health and Ecology Issues. 2010;(1):129-134. (In Russ.) https://doi.org/10.51523/2708-6011.2010-7-1-29
Просмотров: 289
Послать статью по эл. почте 